Lytix Biopharma ASA Cash Flow Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-73	-59.98	-94.27	-87.9	-56.07	-48.08
Depreciation & Amortization	0.99	1	0.92	0.96	0.92	0.45
Stock-Based Compensation	15.55	13.84	0.88	4.18	1.38	4.05
Other Operating Activities	-2.2	-2.32	-1.5	-2.35	-1.35	-0.13
Change in Accounts Receivable	2.63	6.03	-0.34	-6.04	-1.06	-1.51
Change in Accounts Payable	-19.71	-18.43	23.94	-4.83	3.55	0.61
Operating Cash Flow	-75.74	-59.85	-70.37	-95.97	-52.63	-44.61
Capital Expenditures	-	-	-	-0.05	-0.15	-
Investment in Securities	-62.39	-61.76	23.18	27.42	-50.61	-
Other Investing Activities	2.2	2.33	1.51	2.35	1.41	0.14
Investing Cash Flow	-60.19	-59.43	24.69	29.73	-49.36	0.14
Long-Term Debt Repaid	-	-0.9	-0.85	-0.94	-0.83	-0.42
Net Debt Issued (Repaid)	-0.93	-0.9	-0.85	-0.94	-0.83	-0.42
Issuance of Common Stock	77.74	-	161.3	-	0.13	225.21
Other Financing Activities	-1	-0.01	-11.34	-0	-0.06	-11.49
Financing Cash Flow	75.81	-0.91	149.11	-0.94	-0.75	213.3
Miscellaneous Cash Flow Adjustments	-	0	-	-	-	-0
Net Cash Flow	-60.11	-120.19	103.43	-67.19	-102.73	168.83
Free Cash Flow	-75.74	-59.85	-70.37	-96.02	-52.78	-44.61
Free Cash Flow Margin	-	-	-632.05%	-2405.86%	-478.47%	-231.04%
Free Cash Flow Per Share	-1.11	-0.88	-1.30	-2.40	-1.33	-1.34
Cash Interest Paid	0.01	0.01	0.01	0	0.06	0
Levered Free Cash Flow	-50.75	-37.7	-34.62	-66.3	-36.49	-26.43
Unlevered Free Cash Flow	-50.62	-37.57	-34.54	-66.27	-36.4	-26.39
Change in Working Capital	-17.08	-12.39	23.6	-10.87	2.5	-0.9